Company Description
Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland.
The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.
It also provides laboratory-testing services for Sjogren’s syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders.
The company develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia.
It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners.
Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.
| Country | Ireland |
| Founded | 1992 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 380 |
| CEO | John Gillard |
Contact Details
Address: IDA Business Park Bray, A98 H5C8 Ireland | |
| Phone | 353 1 276 9800 |
| Website | trinitybiotech.com |
Stock Details
| Ticker Symbol | TRIB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000888721 |
| CUSIP Number | 896438306 |
| ISIN Number | US8964385046 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| John Gillard | President, Chief Executive Officer, Company Secretary and Director |
| Dr. James Walsh Ph.D. | Executive Director of Business Development and Executive Director |
| Louise Tallon | Chief Financial Officer and Chief Accounting Officer |
| Jacqueline O'Neill | Director of Operations |
| Dr. Gary Keating Ph.D. | Chief Technology Officer |
| Eibhlin Kelly | Chief Information Officer |
| Colm Molloy | Group Director of Human Resources and Culture |
| Adrian Donohue | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 15, 2024 | F-3 | Filing |
| Nov 15, 2024 | 6-K | Report of foreign issuer |
| Nov 14, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Nov 7, 2024 | 6-K | Report of foreign issuer |
| Oct 25, 2024 | 6-K | Report of foreign issuer |
| Oct 25, 2024 | 6-K | Report of foreign issuer |
| Oct 7, 2024 | 6-K | Report of foreign issuer |
| Oct 2, 2024 | 6-K | Report of foreign issuer |
| Sep 30, 2024 | 6-K | Report of foreign issuer |
| Sep 25, 2024 | 6-K | Report of foreign issuer |